Beyond the Birth Certificate: Turning "Biological Age" from a Slogan into a Clinical Practice

 

Why This Guideline Sentence Is Harder Than It Looks

The 2026 ACC/AHA/Multisociety Dyslipidemia Guideline contains one sentence that sounds simple and is not: decisions about lipid-lowering therapy in older adults should not rest on chronologic age alone. Instead, clinicians are told to weigh frailty, functional status, morbidity burden, polypharmacy, and patient preference.

Read quickly, this sounds like an instruction to replace age with something else — a frailty score, a functional test, a vibe of "how old someone really seems." That reading is wrong, and it matters clinically why it is wrong.

Biological age has no independent unit. You cannot measure it the way you measure blood pressure or LDL-C. Every claim that a patient is "biologically younger" or "biologically older" than their years is, by construction, a comparison to same-age peers. A frailty index doesn't discard chronological age — it uses it as the denominator. Saying an 82-year-old has "the frailty profile of a 70-year-old" only makes sense because we know what deficits are typical for 70-year-olds and for 82-year-olds. Take away the calendar age, and the sentence collapses into nonsense.

So the guideline is not asking you to ignore age. It's asking you to stop treating age as sufficient — and to start treating it as the reference frame against which everything else gets interpreted.

What "Implementing" This Actually Means in a Clinic Visit

Most articles stop at the principle. Here is what changes in practice.

Step 1 — Anchor, don't discard. Start every risk conversation with the patient's chronological age and what's typical for that age. This is not a formality; it's the baseline the rest of the assessment depends on. A deficit-accumulation frailty index is only informative when it says "more deficits than expected for 78" or "fewer than expected for 78".

Step 2 — Run a brief deviation check, not a full geriatric workup. You don't need a 70-item Rockwood index in a 20-minute visit. A few minutes of the Fried Frailty Phenotype — grip strength, gait speed over a short distance, unintentional weight loss, exhaustion, activity level — gives a serviceable read on whether this patient sits above, at, or below the norm for their age. Score 0 = robust, 1–2 = prefrail, 3+ = frail. That single number reframes the LLT conversation more usefully than age alone ever could.

Step 3 — Add the two variables the frailty score misses. Frailty tools capture physical reserve well but say little about two things that materially change the LLT decision:

• Polypharmacy load — how many drugs is the patient already managing, and does adding a statin meaningfully raise interaction or adherence risk?

• Vascular exposure history — a patient with lifelong familial hypercholesterolemia or elevated Lp(a) has been accumulating arterial damage since young adulthood, independent of how frail they appear today. Their "vascular age" may be running ahead of their frailty age. This is why genetic/hereditary lipid history belongs in the same conversation as frailty — they're both forms of biological age, but they point in different directions and sometimes disagree.

Step 4 — Ask about recovery, not just current state. One of the more clinically useful reframes: frailty isn't really about resting values, it's about how long someone takes to bounce back after a stressor — an infection, a fall, a hospitalization . Ask the patient (or their chart): after your last illness or minor injury, how long until you felt "normal" again? Slow, incomplete recovery is a stronger signal of narrowed reserve than any single lab value, and it's a marker that's easy to ask about in under a minute.

Step 5 — Reassess at trigger events, not on a calendar. Biological age is not static. Frailty status should be revisited after any of the classic "turning point" events — hospitalization, a fall, a new diagnosis, a period of bed rest — because these are the moments homeokinesis narrows measurably, and a prior LLT decision (start, continue, or stop) may need revisiting. Don't wait for the next annual visit if a triggering event happens in between.

Step 6 — Close with the outcome question, not the biomarker question. The guideline's own conclusion frames this well: the most important question is "what matters most to you?". This isn't a throwaway line — it's the step that actually resolves ambiguous cases. A patient who wants to stay sharp enough to keep gardening or seeing grandchildren answers the initiation/deprescribing question differently than one focused purely on longevity. This is the wellspan question: not how many years, but how many of those years remain recognizably theirs.

A One-Page Decision Sequence

For a quick-reference version, the sequence looks like this:

1. State chronological age and its associated average life expectancy/statin time-to-benefit.

2. Run a brief frailty screen (Fried criteria or similar) — is this patient above, at, or below the norm for their age?

3. Check polypharmacy burden and drug interaction risk.

4. Check hereditary lipid history (FH, elevated Lp(a)) — is vascular age ahead of frailty age?

5. Ask about recovery time after the last acute stressor.

6. Ask directly what outcome the patient values most — years, function, or specific milestones.

7. Match the LLT decision to the composite picture, not to any single input — and flag a trigger-based, not calendar-based, reassessment date.

The Honest Limitation

No validated instrument currently combines all these inputs into a single "biological age for lipid therapy" score. The guideline authors acknowledge this gap themselves, pointing to trials like STAREE and PREVENTABLE as future sources of better tools. Until those arrive, the practical answer is not a better calculator — it's a structured conversation that keeps chronological age as the anchor while systematically layering in the four things a birth certificate can't tell you: physical reserve, drug burden, vascular exposure history, and what the patient actually wants from the years ahead.

You can learn more by reading our e-books 

The Uncharted Architecture of Atherosclerosis: Beyond Lipid Panels — Functional Subspecies, Risk Stratification, and Targeted Therapy

Frailty: Aging as the Accumulation of Vulnerabilities

Ceiling of Life: Between the Dream of Immortality and the Risk of Wasted Years

Mykola Iabluchanskyi together with Andriy Yabluchanskiy